endpts.com·May 21, 2026
Merck's partner Kelun-Biotech reported a successful Phase 3 study in China for the experimental antibody-drug conjugate sac-TMT in lung cancer, raising expectations for its potential effectiveness in Western patients.
The key learning for you is that Kelun-Biotech's Phase 3 success with the antibody-drug conjugate sac-TMT in treating lung cancer in China presents a promising signal for potential expansion into Western markets. This success underscores the strategic importance of monitoring and potentially investing in cross-border biotech collaborations, as positive trial results in one region can significantly influence approvals and market opportunities in others.